LQDA / Liquidia Corporation - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update · YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILD · Positive interim data from ASCENT trial reinforces YUTREPIA’s tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

Indenture of Lease, dated as of June 16, 2025, by and between Liquidia Technologies, Inc. and King Combs LLC.

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. PATHWAY TRIANGLE 1000 SCIENCE DRIVE MORRISVILLE, NORTH CAROLINA LEASE SUMMARY SHEET Execution Date: June 16, 2025 Tenant: Liquidia Technologies, Inc., a Delawar

tree UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents tree UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

Exhibit 99.1 Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ MORRISVILLE, N.C., June 23, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

Exhibit 99.1 Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD · YUTREPIA now available to be prescribed to patients via specialty pharmacies · FDA approved YUTREPIA on May 23, 2025 · Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Exhibit 99.1 U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) · FDA’s approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD · YUTREPIA is designed to enhance deep-lung delivery with a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

Exhibit 99.1 Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics · New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA · ‘782 patent claims same general subject matter as UTHR’s invalidated ‘793 patent · Does not impact

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update · Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025 · District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendment · Fully enrolled Cohort A of ASCENT study in patients with PH-ILD · Further strengthened financial position via acce

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N

LIQUIDIA CORPORATION FINANCIAL STATEMENTS TABLE OF CONTENTS

Exhibit 99.1 Item 8. Financial Statements and Supplementary Data LIQUIDIA CORPORATION FINANCIAL STATEMENTS TABLE OF CONTENTS Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) F-2 Consolidated Balance Sheets as of December 31, 2024 and 2023 F-5 Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024 and 2023 F-6 Consolidated Statement

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 (December 31, 2024) LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

Exhibit 99.1 District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia · Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIA · FDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 MORRISVILLE, N.C., May 2, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.       )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.       ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder

Exhibit 99.1 Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder · FDA sets PDUFA goal date of May 24, 2025 MORRISVILLE, N.C., March 28, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Foo

Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 March 21, 2025

Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 March 21, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

Sixth Amendment to Revenue Interest Financing Agreement, dated as of March 17, 2025, by and between Liquidia Technologies, Inc. and Healthcare Royalty Partners IV, L.P.

Exhibit 10.25 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SIXTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This SIXTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of Ma

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate- Offering Price(2) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common Stock 457(c) 1,123,595 $ 14.

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

First Amendment to Amended and Restated Commercial Manufacturing Services and Supply Agreement, dated January 7, 2025, by and between Liquidia Technologies, Inc. and Lonza Tampa LLC.

Exhibit 10.53 January 7, 2025 VIA: E-MAIL Michael Hunter Vice President, Manufacturing Operations Liquidia Technologies, Inc. 419 Davis Drive, Suite 100 Morrisville, North Carolina 27560 Re: Year 2, Launch Delay Dear Michael, Lonza Tampa LLC (‘‘Lonza’’) and Liquidia Technologies, Inc. (‘‘Liquidia’’) entered into an Amended and Restated Commercial Manufacturing Services and Supply Agreement, dated

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update · Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025 · Advancing pipeline of inhaled treprostinil products in clinical studies · Strengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA

Subsidiaries of Liquidia Corporation.

EXHIBIT 21.1 Liquidia Technologies, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: Liquidia Technologies, Inc. Liquidia PAH, LLC Jurisdiction of organization: Delaware Name under which business conducted: Liquidia PAH, LLC

As filed with the Securities and Exchange Commission on March 19, 2025

As filed with the Securities and Exchange Commission on March 19, 2025 Registration Statement No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million

Exhibit 99.1 Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million MORRISVILLE, N.C., March 18, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it has entered into a sixth amendment to its agreeme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

EIGHTH AMENDMENT TO Lease Agreement

Exhibit 99.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. EIGHTH AMENDMENT TO Lease Agreement THIS EIGHTH AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is entered into effective as of the 22 day of November, 2024 (th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

First Amendment to the License Agreement, dated as of October 2, 2024, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) · U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking

Device License Agreement, dated as of October 2, 2024, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

LQDA / Liquidia Corporation / Manning Paul B - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 4)* Liquidia Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 53635D202 (CUSIP Number) Septe

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent

Exhibit 99.1 United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent - U.S. Supreme Court denied United Therapeutics’ petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalid - Decisions that Liquidia does not infringe any valid claims of the three patents originally asserted by United Therapeutics are now

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

Exhibit 99.1 Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606) · Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere · Liquidia also obtains rights to Pharmosa’s next-generation nebulizers for use with L606 · Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

Fifth Amendment to Revenue Interest Financing Agreement, dated as of September 11, 2024, by and between Liquidia Technologies, Inc. and Healthcare Royalty Partners IV, L.P. (incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on September 12, 2024).

  Exhibit 10.3   Execution Version   CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.   FIFTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT   This FIFTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “

Registration Rights Agreement by and among Liquidia Corporation and the Purchasers, dated September 10, 2024 (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on September 12, 2024).

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of September 10, 2024, by and among Liquidia Corporation, a Delaware corporation (the “Company”) and the purchasers identified on Schedule A hereto (each, a “Purchaser” and collectively, the “Purchasers”) and such other Persons, if any, from time to time, that become a party hereto as holder

Underwriting Agreement by and between Liquidia Corporation and BofA Securities, Inc., as representative of the underwriters named therein, dated September 11, 2024.

  Exhibit 1.1   Execution Version   6,460,674 Shares Liquidia Corporation   UNDERWRITING AGREEMENT   September 11, 2024   BofA Securities, Inc.  As Representative of the several Underwriters   c/o BofA Securities, Inc.  One Bryant Park  New York, New York 10036   Ladies and Gentlemen:   Introductory. Liquidia Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the se

LQDA / Liquidia Corporation / Caligan Partners LP - LIQUIDIA CORP Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Liquidia Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 53635D202 (CUSIP Number) Dav

Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

Common Stock Purchase Agreement by and among Liquidia Corporation and the Purchasers, dated September 10, 2024 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on September 12, 2024).

Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of September 10, 2024, by and among Liquidia Corporation, a Delaware corporation, with headquarters located at 419 Davis Drive, Suite 100, Morrisville, NC 27560 (the “Company”) and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively,

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

Exhibit 99.1 Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement MORRISVILLE, N.C., September 11, 2024 – Liquidia Corporation (NASDAQ: LQDA) (the “Company” or “Liquidia”), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases,

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

Free Writing Prospectus filed pursuant to Rule 433 Registration Statement No. 333-276244 Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement MORRISVILLE, N.C., September 11, 2024 – Liquidia Corporation (NASDAQ: LQDA) (the “Company” or “Liquidia”), a biopharmaceutical company devel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

6,460,674 Shares Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(4)  Registration No. 333-276244 PROSPECTUS SUPPLEMENT (To prospectus dated December 28, 2023) 6,460,674 Shares Common Stock  We are offering 6,460,674 shares of common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “LQDA.” The last reported sale price of our common stock on The Nasdaq Capital Market on September 10,

LQDA / Liquidia Corporation / Caligan Partners LP - LIQUIDIA CORPORATION Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Liquidia Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 53635D202 (CUSIP Number) Dav

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD

Exhibit 99.1 Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD MORRISVILLE, N.C., August 22,2024 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it has filed litig

U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Exhibit 99.1 U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) ● FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise meets the requirements for approval under the Federal Food, D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-

Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update MORRISVILLE, N.C., August 7, 2024 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the second quarter ended June 30, 2024. The company will host a webcast

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 July 2, 2024

Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 July 2, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

As filed with the Securities and Exchange Commission on June 27, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 27, 2024 Registration Statement No.

Filing Fee Table**

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate- Offering Price(2) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common Stock 457(c) 7,322,197 $ 12.

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Certificate of Second Amendment of Certificate of Corporation of Liquidia Corporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2024).

Exhibit 3.1 CERTIFICATE OF SECOND AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF LIQUIDIA CORPORATION Liquidia Corporation, a corporation duly organized and validly existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: The Certificate of Incorporation, as amended, of the Company (the “Certificate of Incorporat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch

Exhibit 99.1 District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch · On May 31, Judge Andrews denied United Therapeutics’ motion for a preliminary injunction to block the launch of YUTREPIA in the PH-ILD indication · Ruling reinforces the clear path for FDA to issue final decision on amended NDA for YUTREPIA to treat both PAH and PH-ILD MORRISVILL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Liquidia Corporation Amended and Restated Executive Severance and Change in Control Plan

Exhibit 10.1 Liquidia Corporation Amended and Restated Executive Severance and Change in Control Plan Table of Contents Page ARTICLE I Statement of Purpose and Effective Date 1 1.01 Purpose 1 1.02 Effective Date 1 ARTICLE II Definitions 1 ARTICLE III Participation and Eligibility for Benefits 8 3.01 Eligibility 8 3.02 Participation 8 3.03 Eligibility for Benefits 8 ARTICLE IV Obligations of the Em

Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update MORRISVILLE, N.C., May 13, 2024 – Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024. The company will host a webcast at 8:30 a.m. ET on May 14, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.       )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.       ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.       )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.       ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R

Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder

Exhibit 99.1 Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder · On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman Litigation · On March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and preliminary injunction in separate litigation filed b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Subsidiaries of Liquidia Corporation.

EXHIBIT 21.1 Liquidia Technologies, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: Liquidia Technologies, Inc. Liquidia PAH, LLC Jurisdiction of organization: Delaware Name under which business conducted: Liquidia PAH, LLC

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update - Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approval - Federal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalid - Advancing industry leading portfolio for inhaled treprostinil with YUTREPIA and sust

Third Amendment to Revenue Interest Financing Agreement, dated as of July 27, 2023, by and between Liquidia Technologies, Inc. and Healthcare Royalty Partners IV, L.P.

Exhibit 10.20 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. EXECUTION VERSION THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

License Agreement, dated as of June 28, 2023, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc.

Exhibit 10.49 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Execution Version LICENSE AGREEMENT dated as of June 28, 2023 by and between Pharmosa Biopharm Inc. and Liquidia Technologies, Inc. Table of Contents Page ARTI

Asset Transfer Agreement, dated as of June 28, 2023, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc.

Exhibit 10.50 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Execution Version ASSET Transfer AGREEMENT This ASSET TRANSFER AGREEMENT (this “Agreement”) is made and entered as of June 28, 2023 (“Effective Date”) by and b

Liquidia Corporation 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 of the Registrant’s Annual Report on 10-K, filed on March 13, 2024).

Exhibit 10.4 LIQUIDIA CORPORATION 2020 LONG-TERM INCENTIVE PLAN TABLE OF CONTENTS 1. History; Existence of the Plan‌1 2. Purposes of the Plan‌1 3. Terminology‌1 4. Administration‌1 (a) Administration of the Plan‌1 (b) Powers of the Administrator‌1 (c) Delegation of Administrative Authority‌3 (d) Non-Uniform Determinations‌3 (e) Limited Liability; Advisors‌3 (f) Indemnification‌3 (g) Effect of Admi

Supply Agreement, dated May 22, 2023, by and between Liquidia Technologies, Inc. and Plastiape SpA.

Exhibit 10.51 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. Supply Agreement (“Agreement”) Parties. 1.Liquidia Technologies, Inc., 419 Davis Dr., Suite 100, Morrisville, NC 27560 United States，email supplychain@liquidia

Second Amendment to Revenue Interest Financing Agreement, dated as of June 28, 2023, by and between Liquidia Technologies, Inc. and Healthcare Royalty Partners IV, L.P.

Exhibit 10.19 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of June 28, 2023 (this

Liquidia Corporation Code of Conduct. (incorporated herein by reference to Exhibit 14.1 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 13, 2024).

Exhibit 14.1 CODE OF CONDUCT As amended on March 8, 2022 TABLE OF CONTENTS INTRODUCTION1 MISSION STATEMENT2 OUR PURPOSE2 OUR PRINCIPLES2 REPORTING VIOLATIONS3 COMPLIANCE3 NO RETALIATION3 MORAL STANDARDS4 CONFLICT OF INTEREST4 Gifts & Entertainment5 Bribes, Kickbacks & Unlawful Payments6 Foreign Corrupt Practices Act7 Anti-Money Laundering 8 Company Assets 8 Competing Outside Employment & Business

As filed with the Securities and Exchange Commission on March 13, 2024

As filed with the Securities and Exchange Commission on March 13, 2024 Registration No.

Amended and Restated Commercial Manufacturing Services and Supply Agreement, dated July 13, 2023, by and between Liquidia Technologies, Inc. and Lonza Tampa LLC.

Exhibit 10.47 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AND SUPPLY AGREEMENT This Amended and Restated Commercial Manufacturing Services and Supply Agreement (t

Form of Non-Qualified Stock Option Agreement under the Liquidia Corporation 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.9 of the Registrant’s Annual Report on Form 10-K, filed on March 13, 2024).

Exhibit 10.9 Grant No.: LIQUIDIA CORPORATION NONSTATUTORY STOCK OPTION NOTICE This Notice evidences the award of nonstatutory stock options (each, an “Option” or collectively, the “Options”) that have been granted to you, [NAME], subject to and conditioned upon your agreement to the terms of the attached Nonstatutory Stock Option Agreement (the “Agreement”). The Options entitle you to purchase sha

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

As filed with the Securities and Exchange Commission on March 13, 2024

As filed with the Securities and Exchange Commission on March 13, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA

Form of Restricted Stock Units Agreement (Performance-Based) under the Liquidia Corporation 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.7 of the Registrant’s Annual Report on Form 10-K, filed on March 13, 2024).

Exhibit 10.7 LIQUIDIA CORPORATION RESTRICTED STOCK UNITS NOTICE (Performance Based) UNDER THE LIQUIDIA CORPORATION 2020 LONG-TERM INCENTIVE PLAN Name of Grantee: This Notice evidences the award of performance-based restricted stock units (each, an “RSU,” and collectively, the “RSUs”) of LIQUIDIA Corporation, a Delaware corporation (the “Company”), that have been granted to you pursuant to the Liqu

Description of Securities of the Company.

Exhibit 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The only class of securities of Liquidia Corporation, a Delaware corporation (the “Company”), registered under Section 12 of the Securities Exchange Act of 1934, as amended, is common stock, par value $0.001 per share (“common stock”). The following description of the Com

Form of Incentive Stock Option Agreement under the Liquidia Corporation 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.8 of the Registrant’s Annual Report on Form 10-K, filed on March 13, 2024).

Exhibit 10.8 Grant No.: LIQUIDIA CORPORATION INCENTIVE STOCK OPTION NOTICE This Notice evidences the award of stock options (each, an “Option” or collectively, the “Options”) that have been granted to you, [NAME], subject to and conditioned upon your agreement to the terms of the attached Incentive Stock Option Agreement (the “Agreement”). The Options entitle you to purchase shares of common stock

Form of Restricted Stock Units Agreement under the Liquidia Corporation 2020 Long-term Incentive Plan (incorporated by reference to Exhibit 10.6 of the Registrant’s Annual Report on Form 10-K, filed on March 13, 2024).

Exhibit 10.6 LIQUIDIA CORPORATION RESTRICTED STOCK UNITS NOTICE UNDER THE LIQUIDIA CORPORATION 2020 LONG-TERM INCENTIVE PLAN Name of Grantee: This Notice evidences the award of restricted stock units (each, an “RSU,” and collectively, the “RSUs”) of LIQUIDIA Corporation, a Delaware corporation (the “Company”), that have been granted to you pursuant to the Liquidia Corporation 2020 Long-Term Incent

LQDA / Liquidia Corporation / Manning Paul B - SC 13G/A Passive Investment

SC 13G/A 1 tm245987d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 3)* Liquidia Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

Exhibit 99.1 Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder MORRISVILLE, N.C., January 25, 2024 - Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat pul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F

CONFIDENTIAL INFORMATION

Exhibit 99.1 CONFIDENTIAL INFORMATION Liquidia Corporation Announces Updates to Operations Leadership MORRISVILLE, N.C., January 19, 2024 – Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the potential approval and launch of YUTREPIA™ (treprostinil) inhalation powder. Michael Kaseta, Chief Financial Off

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F

LQDA / Liquidia Corporation / Legend Aggregator, LP - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Liquidia Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 53635D202 (CUSIP Number) January 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

Joint Filing Agreement

EX-99.A 2 d590854dex99a.htm EX-99.A Exhibit A Joint Filing Agreement The undersigned hereby agree to the joint filing on behalf of each of them of the Statement on Schedule 13G with respect to the Common Stock of Liquidia Corporation, and any further amendments to such statement on Schedule 13G executed by each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Se

Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Exhibit 99.1 Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD January 5, 2024 • Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA • Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C., January 5, 2024 (GLOBE NEWSWIRE) - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) p

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Exhibit 99.2 Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims January 8, 2024 • Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal Circuit • Requests declaration that ’327 patent is not infringed, is invalid and is unenforceable • Files counterclaims asserting United Therapeuti

Common Stock Purchase Agreement, dated as of January 4, 2024, by and between Liquidia Corporation and the Purchaser (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on January 8, 2024).

Exhibit 10.2 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of January 4, 2024, by and among Liquidia Corporation, a Delaware corporation, with headquarters located at 419 Davis Drive, Suite 100, Morrisville, NC 27560 (the “Company”) and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

Fourth Amendment to Revenue Interest Financing Agreement, dated as of January 3, 2024, by and between Liquidia Technologies, Inc. and Healthcare Royalty Partners IV, L.P. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 8, 2024).

Exhibit 10.1 Execution Version * Certain terms of this Exhibit 10.1 have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as they are both not material and of the type that the registrant treats as private or confidential. FOURTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This FOURTH AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of Janu

Registration Rights Agreement, dated as of January 4, 2024, by and between Liquidia Corporation and the Purchaser (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on January 8, 2024).

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of January 4, 2024, by and among Liquidia Corporation, a Delaware corporation (the “Company”) and the purchasers identified on Schedule A hereto (each, a “Purchaser” and collectively, the “Purchasers”) and such other Persons, if any, from time to time, that become a party hereto as holders o

Liquidia Corporation Announces $100 Million in New Financings

Exhibit 99.1 Liquidia Corporation Announces $100 Million in New Financings - Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement - Additional advance of $25.0 million from HealthCare Royalty under current financing agreement MORRISVILLE, N.C., January 4, 2024 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced tod

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 December 29, 2023

Liquidia Corporation 419 Davis Drive, Suite 100 Morrisville, NC 27560 December 29, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

As filed with the Securities and Exchange Commission on December 28, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 28, 2023 Registration Statement No.

Form of Subordinated Indenture*

Exhibit 4.9 LIQUIDA CORPORATION and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) I

Filing Fee Table*

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0.

Form of Senior Indenture*

Exhibit 4.8 LIQUIDA CORPORATION and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inappli

As filed with the Securities and Exchange Commission on December 22, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 22, 2023 Registration Statement No.

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

Exhibit 99.1 U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent) - Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalation - Liquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., December 20, 2023 - Liquidia Corporation (NASDAQ: LQDA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

LQDA / Liquidia Corp / Caligan Partners LP - LIQUIDIA CORPORATION Activist Investment

SC 13D/A 1 p23-2975sc13da.htm LIQUIDIA CORPORATION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Liquidia Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title o

Underwriting Agreement by and between Liquidia Corporation and BofA Securities, Inc., as representative of the underwriters named therein, dated December 12, 2023.

Exhibit 1.1 Execution Version 3,491,620 Shares Liquidia Corporation UNDERWRITING AGREEMENT December 12, 2023 BofA Securities, Inc. As Representative of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Introductory. Liquidia Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters nam

Purchase Agreement by and between Liquidia Corporation and Roger Jeffs, dated December 12, 2023 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on December 14, 2023).

Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of December 12, 2023, by and among Liquidia Corporation, a Delaware corporation, with headquarters located at 419 Davis Drive, Suite 100, Morrisville, NC 27560 (the “Company”) and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 (December 12, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 (December 12, 2023) LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorpo

3,491,620 Shares Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(2)  Registration No. 333-251394 PROSPECTUS SUPPLEMENT (To prospectus dated December 23, 2020) 3,491,620 Shares Common Stock We are offering 3,491,620 shares of common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “LQDA.” The last reported sale price of our common stock on The Nasdaq Capital Market on December 11, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

Liquidia Announces Pricing of Public Offering of Common Stock

Exhibit 99.1 Liquidia Announces Pricing of Public Offering of Common Stock RESEARCH TRIANGLE PARK, N.C., December 12, 2023 - Liquidia Corporation (NASDAQ: LQDA) announced today that it has priced an underwritten public offering of 3,491,620 shares of common stock at a public offering price of $7.16 for total gross proceeds of approximately $25.0 million, before deducting underwriting discounts and

Calculation of Filing Fee Tables (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:

Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update · Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023 · PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024 · Hired sales force in preparation of potential positive legal and regulatory outcomes MORRISVILLE, N.C., November 7, 2023 - Liquidia Co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F

Liquidia Corporation Policy for Recovery of Erroneously Awarded Incentive Compensation (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 7, 2023).

Exhibit 10.1 liquidia corporation Policy for RECOVERY OF ERRONEOUSLY AWARDED Incentive Compensation (Adopted: November 2, 2023) 1. INTRODUCTION Liquidia Corporation, a Delaware corporation (the “Company”) is adopting this policy (this “Policy”) to provide for the Company’s recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below) unde

FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label

Exhibit 99.1 FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label · Sets PDUFA goal date of January 24, 2024 · If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., September 25, 2023 - Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s amendment to the te

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

Exhibit 99.1 United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office · Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ label · Litigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

Supply Agreement, dated May 22, 2023, by and between Liquidia Technologies, Inc. and Plastiape SpA.

Exhibit 10.5 Supply Agreement (“Agreement”) Parties. 1.Liquidia Technologies, Inc., 419 Davis Dr., Suite 100, Morrisville, NC 27560 United States，email [email protected] ( “Liquidia”). 2.Plastiape SpA of 23875 Osnago (Lecco) - Via 1 Maggio, 8, Italy facsimile +39 039 587805 email [email protected] (“Plastiape” and, collectively with Liquidia, the “Parties” and each a “Party”). Int

License Agreement, dated as of June 28, 2023, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc.

Exhibit 10.3 LICENSE AGREEMENT dated as of June 28, 2023 by and between Pharmosa Biopharm Inc. and Liquidia Technologies, Inc. Table of Contents Page ARTICLE 1 Definitions‌1 ARTICLE 2 Licenses AND OTHER RIGHTS‌10 2.1 Grant of License to Company‌10 2.2 Grant of Sublicense by Company‌10 2.3 Licensor Technology Transfer‌11 2.4 Regulatory Technology Transfer and Existing Third Party Agreements‌11 2.5

Second Amendment to Revenue Interest Financing Agreement, dated as of June 28, 2023, by and between Liquidia Technologies, Inc. and Healthcare Royalty Partners IV, L.P.

Exhibit 10.1 SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This SECOND AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of June 28, 2023 (this “Amendment”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership, as the sole Investor and Inve

Asset Transfer Agreement, dated as of June 28, 2023, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc.

Exhibit 10.4 ASSET Transfer AGREEMENT This ASSET TRANSFER AGREEMENT (this “Agreement”) is made and entered as of June 28, 2023 (“Effective Date”) by and between Pharmosa Biopharm Inc., a corporation incorporated under the laws of Taiwan having a place of business at 3F.-3, No. 66, Sanchong Road, Nangang District, Taipei City 11502, Taiwan (“Seller”), and Liquidia Technologies, Inc., a corporation

Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update MORRISVILLE, N.C., August 10, 2023 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-

Certificate of Amendment of Certificate of Incorporation of Liquidia Corporation (incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 10, 2023).

Exhibit 3.1 ACTIVE\600390586.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF LIQUIDIA CORPORATION Liquidia Corporation, a corporation duly organized and validly existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: The Certificate of Incorporation of the Company is hereby amended by deleting th

Amended and Restated Commercial Manufacturing Services and Supply Agreement, dated July 13, 2023, by and between Liquidia Technologies, Inc. and Lonza Tampa LLC.

Exhibit 10.6 AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AND SUPPLY AGREEMENT This Amended and Restated Commercial Manufacturing Services and Supply Agreement (the “Agreement”) is made and entered into as of July 13, 2023 (“Effective Date”), by and between Liquidia Technologies, Inc., with a principal place of business at 419 Davis Drive, Suite 100, Morrisville NC 27560 (“Customer”), an

Third Amendment to Revenue Interest Financing Agreement, dated as of July 27, 2023, by and between Liquidia Technologies, Inc. and Healthcare Royalty Partners IV, L.P.

Exhibit 10.2 THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This THIRD AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”), dated as of July 27, 2023 (the “Amendment Effective Date”), is entered into by and between Liquidia Technologies, Inc., a Delaware corporation (the “Company”), and Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership

Confidential Information

Exhibit 99.1 Confidential Information Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder Confidential Information - No new clinical data is required to add PH-ILD indication as per FDA correspondence - Recertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for Tyvaso - Preparing for potenti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Exhibit 99.1 U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation - Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR - Federal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024 - If PTAB decision affirmed, Liquidia will request final regulatory approval for YUTREPIA™ (treprostinil) inhalat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America

Exhibit 99.1 Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America · Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer · Liquidia funds $10 million upfront payment from finance agreement with Heal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Fourth Amendment to Promotion Agreement, dated as of March 10, 2023, by and between Liquidia PAH, LLC and Sandoz Inc (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on May 8, 2023).

Exhibit 10.1 FOURTH AMENDMENT TO PROMOTION AGREEMENT This Fourth Amendment to Promotion Agreement (this “Fourth Amendment”), is entered into as of March 10, 2023 (the “Fourth Amendment Effective Date”) by and between Sandoz Inc. (“Sandoz”) and Liquidia PAH, LLC, formerly known as RareGen, LLC (“RareGen”). BACKGROUND WHEREAS, Sandoz and RareGen are parties to that certain Promotion Agreement, dated

Research License Agreement, dated as of March 31, 2023, by and between Liquidia Technologies, Inc. and Glaxo Group Limited. (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on May 8, 2023).

Exhibit 10.2 RESEARCH LICENSE AGREEMENT This Research License Agreement (the “Agreement”) is entered into as of March 31, 2023 (the “Effective Date”) by and between Liquidia Technologies, Inc., a Delaware corporation, having its principal place of business at 419 Davis Dr., Suite 100, Morrisville, NC 27560 (“Liquidia”), and Glaxo Group Limited, a company organized and existing under the laws of En

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001

First Amendment to Revenue Interest Financing Agreement, dated as of April 17, 2023, by and among Liquidia Technologies, Inc., Healthcare Royalty Partners IV, L.P., and HCR Collateral Management, LLC. (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q, filed with the SEC on May 8, 2023).

Exhibit 10.3 FIRST AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT This FIRST AMENDMENT TO THE REVENUE INTEREST FINANCING AGREEMENT, dated as of April 17, 2023 (this “Amendment”), is entered into by and among Liquidia Technologies, Inc., a Delaware corporation (the “Company”), Healthcare Royalty Partners IV, L.P., a Delaware limited liability partnership (the “Investor”), and HCR Collateral

LIQUIDIA FIRST QUARTER 2023 FINANCIAL RESULTS AND CORPORATE UPDATE CONFERENCE CALL

Exhibit 99.2 LIQUIDIA FIRST QUARTER 2023 FINANCIAL RESULTS AND CORPORATE UPDATE CONFERENCE CALL Thursday May 4, 2023 at 8:30 AM ET OPERATOR: Good morning and welcome everyone to the Liquidia Corporation First Quarter 2023 Financial Results and Corporate Update conference call. My name is Lisa and I will be your conference operator today. Currently, all participants are in a listen-only mode. Follo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File N

Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update MORRISVILLE, N.C., May 4, 2023 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the first quarter ended March 31, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. Roger

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications

Exhibit 99.1 Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications - New agreement supersedes the collaboration agreement entered in 2012 - GSK retains non-exclusive right to use PRINT for pre-clinical research for inhaled delivery - Liquidia can apply PRINT to any inhaled application other than identified GSK proprietary molecules MORRISVILLE, N.C., April 3, 2023 - Liq

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

As filed with the Securities and Exchange Commission on March 20, 2023

As filed with the Securities and Exchange Commission on March 20, 2023 Registration No.

As filed with the Securities and Exchange Commission on March 20, 2023

As filed with the Securities and Exchange Commission on March 20, 2023 Registration No.

Third Amendment to Promotion Agreement, dated as of November 18, 2022 by and between Liquidia PAH, LLC and Sandoz Inc. (incorporated by reference to Exhibit 10.39 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 20, 2023).

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Device Development and Supply Agreement, dated as of December 1, 2022, by and among Mainbridge Health Partners, LLC, Sandoz Inc. and Liquidia PAH, LLC (incorporated by reference to Exhibit 10.43 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 20, 2023).

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39724 LIQUIDIA

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

Subsidiaries of Liquidia Corporation.

EXHIBIT 21.1 Liquidia Technologies, Inc. Jurisdiction of incorporation: Delaware Name under which business conducted: Liquidia Technologies, Inc. Liquidia PAH, LLC Jurisdiction of organization: Delaware Name under which business conducted: Liquidia PAH, LLC

Revenue Interest Financing Agreement, dated as of January 9, 2023, by and among Liquidia Technologies, Inc., Healthcare Royalty Partners IV, L.P., and HCR Collateral Management, LLC (incorporated by reference to Exhibit 10.11 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 20, 2023).

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update - Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 - Fortified financial position through 2024 - Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 16, 2023 - Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

LQDA / Liquidia Technologies Inc / Manning Paul B - AMENDMENT TO FORM SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 (Amendment No. 2)* Liquidia Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 53635D202 (CUSIP Number) Decem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F

Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)

Exhibit 99.1 Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent) - PTAB rejects UTHR’s request for rehearing of its decision in the inter partes review of the ‘793 Patent (‘793 IPR) - PTAB clarified grounds upon which it based its finding that the cited publications, which invalidated the claims, constit

LQDA / Liquidia Technologies Inc / Canaan VIII LP - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Liquidia Corporation (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 53635D202 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F

Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million

Exhibit 99.1 Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million - Extends cash-runway through at least 2024 - Provides flexibility to accelerate launch preparations timed with success in litigation MORRISVILLE, N.C., January 9, 2023 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that it has entered into a Reve

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F

Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)

Exhibit 99.1 Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH) - Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new infusion pump - Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRI

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F

Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Exhibit 99.1 Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., November 8, 2022 - Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the third quarter ended September 30, 2022. The Company will host a webcast and conference cal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission F

Precedential Opinion Panel Denies United Therapeutics’ Request for Review of ‘793

Exhibit 99.1 Precedential Opinion Panel Denies United Therapeutics? Request for Review of ?793 Inter Partes Review Decision MORRISVILLE, N.C., October 27, 2022 - Liquidia Corporation (NASDAQ: LQDA) announced today that on October 26, 2022, the Precedential Opinion Panel (POP) of the United States Patent and Trademark Office (USPTO) denied a request by United Therapeutics (UTC) to review the decisi

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fi

Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T.

Exhibit 99.1 Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T. - District Court ruling was favorable on ?066 patent and unfavorable on ?793 patent - All patent claims asserted have been found to be either invalid or not infringed by District Court or U.S. Patent Trial and Appeal Board (PTAB) - PTAB decision to invalidate all claims of ?793 pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent

Exhibit 99.1 Liquidia Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent MORRISVILLE, N.C., July 19, 2022 - Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 10,716,793 (?793 patent) owned by United Therapeutics Corporation (UT

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Severance Agreement and General Release, dated as of June 28, 2022, by and between Liquidia Technologies, Inc. and Tushar Shah, M.D.

Exhibit 10.1 SEVERANCE AGREEMENT AND GENERAL RELEASE This SEVERANCE AGREEMENT AND GENERAL RELEASE (?Agreement?) is made and entered into by Liquidia Technologies, Inc. (the ?Company?) and Tushar Shah, M.D. (?Employee?). Throughout the remainder of the Agreement, the Company and Employee may be collectively referred to as the ?Parties.? Employee has entered into an Executive Employment Agreement wi

Executive Employment Agreement, dated as of June 13, 2022, by and between Liquidia Technologies, Inc. and Rajeev Saggar.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into effective June 13th, 2022 2022 (the ?Effective Date?), by and between Rajeev Saggar (?Executive?) and Liquidia Technologies, Inc., a Delaware corporation (the ?Company?). Each of the Company and Executive is a ?Party? and, collectively, they are the ?Parties.? The Company desires to em

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Amendment to the Liquidia Corporation 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on June 17, 2022).

Exhibit 10.1 AMENDMENT TO THE LIQUIDIA CORPORATION 2020 LONG-TERM INCENTIVE PLAN The Board of Directors (the ?Board?) of Liquidia Corporation, a Delaware corporation (the ?Company?), hereby makes this Amendment (this ?Amendment?) to the Liquidia Corporation 2020 Long-Term Incentive Plan (the ?Plan?), this 19th day of April 2022. Subject to the approval of the Company?s shareholders at the 2022 Ann

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.      )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??????) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?

Liquidia Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option

Exhibit 99.3 Liquidia Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option MORRISVLLE, N.C., April 18, 2022 - Liquidia Corporation (NASDAQ: LQDA) (?Liquidia?) today announced the closing of its previously announced underwritten public offering of 11,274,510shares of its common stock, which includes full exercise of the underwriters? over-allotment option

Underwriting Agreement by and between Liquidia Corporation and BofA Securities, Inc., as representative of the underwriters named therein, dated April 12, 2022.

Exhibit 1.1 9,803,922 Shares Liquidia Corporation UNDERWRITING AGREEMENT April 12, 2022 BofA Securities, Inc. As Representative of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Introductory. Liquidia Corporation, a Delaware corporation (the ?Company?), proposes to issue and sell to the several underwriters named in Schedule A (the

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

Liquidia Announces Proposed Offering of Common Stock

Exhibit 99.1 Liquidia Announces Proposed Offering of Common Stock MORRISVILLE, N.C., April 12, 2022 - Liquidia Corporation (NASDAQ: LQDA) (?Liquidia?) announced today that it has commenced an underwritten public offering of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liquidia expects to grant the underwriters a 30-day option to purchase up to

Liquidia Announces Pricing of Public Offering of Common Stock

Exhibit 99.2 Liquidia Announces Pricing of Public Offering of Common Stock MORRISVLLE, N.C., April 12, 2022 - Liquidia Corporation (NASDAQ: LQDA) (?Liquidia?) announced the pricing of an underwritten public offering of 9,803,922 shares of its common stock at a public offering price of $5.10, for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commis

Calculation of Filing Fee Tables (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) LIQUIDIA CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0.

9,803,922 Shares Common Stock

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ?Registration No. 333-251394? PROSPECTUS SUPPLEMENT (To prospectus dated December 23, 2020) 9,803,922 Shares Common Stock ? We are offering 9,803,922 shares of common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol ?LQDA.? The last reported sale price of our common stock on The Nasdaq Capital Market on April 11, 20

Subject to completion, dated April 12, 2022

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission File

Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update - Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder - Expanded use of Treprostinil Injection to include subcutaneous administratio

Exhibit 99.1 Liquidia Corporation Reports Full-Year 2021 Financial Results and Provides Corporate Update - Received tentative FDA approval of YUTREPIA? (treprostinil) inhalation powder - Expanded use of Treprostinil Injection to include subcutaneous administration - Preparing to launch YUTREPIA in late-2022 pending final FDA approval - Company to host webcast and conference call today at 8:30 a.m.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 LIQUIDIA CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39724 85-1710962 (State or other jurisdiction of incorporation) (Commission Fil

Subsidiaries of Liquidia Corporation.

EXHIBIT 21.1 ? Liquidia Technologies, Inc. ? Jurisdiction of incorporation: Delaware Name under which business conducted: Liquidia Technologies, Inc. ? Liquidia PAH, LLC ? Jurisdiction of organization: Delaware Name under which business conducted: Liquidia PAH, LLC ?

As filed with the Securities and Exchange Commission on March 17, 2022

As filed with the Securities and Exchange Commission on March 17, 2022 Registration No.

LIQ861 API Supply Agreement, dated as of January 10, 2020, by and among LGM Pharma LLC, Yonsung Fine Chemicals Co. Ltd. and Liquidia Technologies, Inc. (incorporated herein by reference to Exhibit 10.44 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 17, 2022).

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

As filed with the Securities and Exchange Commission on March 17, 2022

As filed with the Securities and Exchange Commission on March 17, 2022 Registration No.

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

Commercial Manufacturing Services and Supply Agreement, dated November 12, 2020, by and between Liquidia Technologies, Inc. and Xcelience, LLC.

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Filing Fee Table (filed herewith).

Exhibit 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Liquidia Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.

As filed with the Securities and Exchange Commission on March 17, 2022

As filed with the Securities and Exchange Commission on March 17, 2022 Registration No.